Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $4.00 price target on X4 Pharmaceuticals (NASDAQ: XFOR).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE